Name | Title | Contact Details |
---|
Mar Cor Purification/Fluid Solutions is a Drexel Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Apicore, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!
Imaging Endpoints (IE) is an imaging research and core laboratory that provides imaging CRO services to evaluate drug and device efficacy. We specialize in providing the industry`s leading radiology expertise and most advanced technologies through exquisite service. • LOCATIONS: Imaging Endpoints is based in Scottsdale, AZ, with offices in Waltham, MA, and Hyderabad, India as well as new offices opening soon in Basel, Switzerland; Amsterdam, the Netherlands and Shanghai, China. • AFFILIATES: We are an affiliate of HonorHealth, one of the largest healthcare systems nationally. We are also an affiliate of Scottsdale Medical Imaging, Ltd., part of the largest private radiology group in the US. • DEEP SCIENCE: Our Medical and Scientific Affairs Team includes world-class leaders in imaging science. Over 50 publications in leading journals have established us as a technology leader. IE`s experience spans hundreds of successful studies across all phases of development, including the most complex and high-profile Phase 3 trials in the industry. • EXPERT READERS: Our team includes over 100 physician readers comprised of 40 in-house radiologists and academically based expert radiologists, oncologists, surgeons and other physicians in the US. • GLOBAL SERVICES: We are one of the largest global imaging CROs in oncology. We receive/read scans in real-time from hundreds of imaging sites in over 35 countries. • SETTING NEW QUALITY STANDARDS: Our imaging Quality Management System (iQMS) is designed to exceed industry standards. All inspections by FDA and EMEA have resulted in zero observations, clearly demonstrating our leadership in quality. • EXCEPTIONAL STABILITY: IE has experienced a decade of high growth with no ownership change or executive leadership change in over five years.